?We are pleased to take the significant step of initiating the Phase 3 clinical trial at sites around the world,? said Takashi Nagao, CEO and President of Medicago. ?This brings us one step closer to delivering an important new COVID-19 vaccine and contributing to the global fight against the pandemic along with our partner GSK.? Thomas Breuer, Chief Medical Officer, GSK Vaccines said, ?This advance to late stage clinical testing further reinforces our confidence in the adjuvanted vaccine candidate?s potential to make a difference in the continued fight against COVID-19. We look forward to sharing results later this year.? Medicago?s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK?s pandemic adjuvant. Two doses of 3.75 micrograms of CoVLP are administered 21 days apart. The vaccine candidate, in combination with the pandemic adjuvant, was granted Fast Track designation by the US Food and Drug Administration (FDA) on February 17, 2021. Fast Track designation allows the FDA to expedite the development and review of new medicines and vaccines intended to treat or prevent serious conditions and address an unmet medical need. ?The FDA?s decision to grant Fast Track designation for Medicago?s vaccine candidate will help us expedite our efforts to bring the first plant-derived COVID-19 vaccine to market, subject to regulatory approval,? said Carolyn Finkle, Chief Operating Officer of Medicago. ?We are grateful to the FDA and look forward to continuing to work with them as we move forward in our clinical trials, planned application for Emergency Use Authorization, and eventual vaccine licensure application process.? The Phase 3 portion of the study is an event-driven, randomized, observer-blinded, placebo-controlled, two-way cross-over design that will evaluate the efficacy and safety of the adjuvanted CoVLP formulation, compared to placebo. The study will enroll up to 30,000 subjects initially composed of healthy adults (18y to 65y), followed by elderly adults (65y+) and adults with comorbidities. The trial will take place in 10 countries pending regulatory approvals, starting with Canada and the United States, and will enroll males and females from ethnically and racially diverse populations. Information about how to participate in this clinical trial is available at?http://www.CoVLPvaccine.com. The Phase 2 portion of the trial is approaching completion and results are expected to be made publicly available in April 2021. About Medicago Medicago is on a mission to improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-derived therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 450 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. For more information:?www.medicago.com About GSK and its commitment to tackling COVID-19 GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit?www.gsk.com/about-us. GSK is collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people. GSK does not expect to profit from COVID-19 vaccines during the pandemic phase and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness, either through GSK internal investments or with external partners.